Therefore, by specifically inhibiting HDAC, HDACis could remove epigenetic silencing and improve the sensitivity of breast cancer cells to endocrine therapy to a certain extent (Fig. 4E) [83]. Here, HDAC9 is linked to breast carcinoma.